SavedAdd your journal

Journals / The Anatolian Journal of Cardiology / 2020 / Cilt: 24 - Sayı: 4

Ambrisentan-induced severe asymptomatic thrombocytopenia

Dana KİGİTOVİCA
Mat ss ABLİNSKİS
Sanda LEJNİECE
Aivars LEJNİEKS
Andris SKRİDE
Pages
285–286
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

KİGİTOVİCA, D., ABLİNSKİS, M. S., LEJNİECE, S., LEJNİEKS, A., SKRİDE, A. (2020). Ambrisentan-induced severe asymptomatic thrombocytopenia. The Anatolian Journal of Cardiology, Cilt: 24 - Sayı: 4, 285–286. https://ajindex.com/articles/366249

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Fischer A, Denton CP, Matucci-Cerinic M, Gillies H, Blair C, Tislow J, et al. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. Respir Med 2016; 117: 254-63
  2. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al.; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67-119
  3. Buckley MS, Wicks LM, Staib RL, Kirejczyk AK, Varker AS, Gibson JJ, et al. Pharmacokinetic evaluation of ambrisentan. Expert Opin Drug Metab Toxicol 2011; 7: 371-80
  4. Wei A, Gu Z, Li J, Liu X, Wu X, Han Y, et al. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind PlaceboControlled Clinical Trials. J Am Heart Assoc 2016; 5; doi: 10.1161/ JAHA.116.003896
  5. A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB321 (NCT00423202) (cited 2020 Feb 19). Available from: URL; https:// clinicaltrials.gov/ct2/show/NCT00578786 6. Raja SG. Endothelin receptor antagonists for pulmonary arterial hypertension: an overview. Cardiovasc Ther 2010; 28: e65-71
  6. Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev 2013; 27: 137-45
  7. George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evalution and managment. Hematology Am Soc Hematol Educ Program 2009; 153-8
  8. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 580-7
  9. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis and management. J Thromb Haemost 2009; 7: 911-8.